Wire · operational-macro
Hims Agrees to Stop Selling Compounded Lilly Obesity Drugs as Zepbound and Foundayo ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 November 2026 · Fusion42 review
Hims agreed to stop selling compounded versions of Eli Lilly's obesity drugs as part of a deal to sell Lilly's FDA-approved Zepbound and Foundayo directly via its platform. The agreement addresses safety concerns with compounded GLP-1 drugs and aligns Hims with Lilly's direct-to-consumer pricing model, though compounded versions remain available through other sellers.
This Wire brief sits within Fusion42's coverage of Health: Digital Health, and 5 sources have reported it between 6 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
You must drop unapproved compounded GLP-1 offerings now that Lilly restricts these drugs to authorised channels, or lose access to direct pharma supply and risk safety liability. Partnering with Lilly opens a direct sales channel at established prices but cuts your margin flexibility.
◆ Coverage
5 sources · first reported 6 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics